Pages that link to "Q33476082"

The following pages link to Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers (Q33476082):

Displaying 43 items.

• The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies (Q21129302) (← links)
• Liver Metastasis of a Triple-Negative Breast Cancer and Complete Remission for 5 Years After Treatment With Combined Bevacizumab/Paclitaxel/Carboplatin: Case Report and Review of the Literature (Q26779880) (← links)
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial (Q30080035) (← links)
• Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy (Q33827045) (← links)
• The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers (Q33962070) (← links)
• Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy (Q34113473) (← links)
• Treatment options for patients with triple-negative breast cancer (Q34331406) (← links)
• Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo (Q34619763) (← links)
• Management Options in Triple-Negative Breast Cancer (Q35155460) (← links)
• Drug therapy for hereditary cancers (Q35208929) (← links)
• Platinum resistance in breast and ovarian cancer cell lines (Q35397906) (← links)
• Prophylactic and Therapeutic Breast Conservation in BRCA1/2 Mutation Carriers (Q35684391) (← links)
• Novel genetic markers of breast cancer survival identified by a genome-wide association study (Q35803492) (← links)
• Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers (Q35977371) (← links)
• Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma (Q36737616) (← links)
• Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer (Q36814437) (← links)
• Durable Clinical Benefit of Pertuzumab in a Young Patient with BRCA2 Mutation and HER2-Overexpressing Breast Cancer Involving the Brain (Q36855453) (← links)
• Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers (Q36896061) (← links)
• Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer (Q36924418) (← links)
• Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review (Q37128739) (← links)
• Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis (Q37328846) (← links)
• Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations (Q37379689) (← links)
• Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer (Q37532636) (← links)
• Triple-negative breast cancer--current status and future directions (Q37630082) (← links)
• Tumor size and survival in breast cancer--a reappraisal (Q37716590) (← links)
• Therapeutic potential of PARP inhibitors for metastatic breast cancer (Q37931893) (← links)
• Systemic therapy options in BRCA mutation-associated breast cancer (Q38025991) (← links)
• Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers (Q38087850) (← links)
• Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis (Q38190905) (← links)
• Therapies for triple negative breast cancer (Q38424397) (← links)
• Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status (Q38727177) (← links)
• Frequent alterations of homologous recombination repair pathway in primary and chemotolerant breast carcinomas: clinical importance (Q38744918) (← links)
• 3'-Phosphoadenosine 5'-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents (Q38848421) (← links)
• BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers (Q40074639) (← links)
• Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women. (Q40258706) (← links)
• Surgical Treatment of Breast Cancer in BRCA-Mutation Carriers (Q42316325) (← links)
• Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer (Q42474391) (← links)
• Should BRCA2 mutation carriers avoid neoadjuvant chemotherapy? (Q43779858) (← links)
• Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers. (Q48163701) (← links)
• Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation (Q50912716) (← links)
• Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy (Q54644370) (← links)
• BRCA in breast cancer: ESMO Clinical Practice Guidelines (Q59274104) (← links)
• Targeting Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives? (Q60959613) (← links)